EGFR and neoplasm: a tempting approach involving targets that are not in cancer cells is to combine anti-EGFR agents with drugs that may enhance the immune system response against the tumor; for example, with an anti-cytotoxic T lymphocyte antigen 4 (anti-CTLa-4) antibody such as ipilimumab (Lipson and Drake, 2011).